Ionis Pharmaceuticals, Inc. (IONS)
IONS Stock Price Chart
Explore Ionis Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze IONS price movements and trends.
IONS Company Profile
Discover essential business fundamentals and corporate details for Ionis Pharmaceuticals, Inc. (IONS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 May 1991
Employees
1.07K
Website
https://www.ionispharma.comCEO
Brett P. Monia
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Financial Timeline
Browse a chronological timeline of Ionis Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Upcoming earnings on 17 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$1.15.
Earnings released on 30 Jul 2025
EPS came in at $0.86 surpassing the estimated $0.27 by +218.52%, while revenue for the quarter reached $452.05M , beating expectations by +241.94%.
Earnings released on 30 Apr 2025
EPS came in at -$0.75 surpassing the estimated -$1.11 by +32.43%, while revenue for the quarter reached $131.61M , missing expectations by -12.60%.
Earnings released on 19 Feb 2025
EPS came in at -$0.66 surpassing the estimated -$1.09 by +39.45%, while revenue for the quarter reached $226.58M , beating expectations by +72.78%.
Earnings released on 6 Nov 2024
EPS came in at -$0.95 surpassing the estimated -$1.16 by +18.10%, while revenue for the quarter reached $134.00M , missing expectations by -7.23%.
Earnings released on 1 Aug 2024
EPS came in at -$0.45 surpassing the estimated -$0.95 by +52.63%, while revenue for the quarter reached $225.25M , beating expectations by +50.10%.
Earnings released on 7 May 2024
EPS came in at -$0.98 surpassing the estimated -$1.10 by +10.91%, while revenue for the quarter reached $119.50M , missing expectations by -12.09%.
Earnings released on 21 Feb 2024
EPS came in at -$0.06 surpassing the estimated -$0.78 by +92.31%, while revenue for the quarter reached $324.51M , beating expectations by +85.69%.
Earnings released on 2 Nov 2023
EPS came in at -$1.03 falling short of the estimated -$1.01 by -1.98%, while revenue for the quarter reached $144.00M , beating expectations by +8.35%.
Earnings released on 9 Aug 2023
EPS came in at -$0.60 surpassing the estimated -$0.94 by +36.17%, while revenue for the quarter reached $188.00M , beating expectations by +35.42%.
Earnings released on 3 May 2023
EPS came in at -$0.87 surpassing the estimated -$1.00 by +13.00%, while revenue for the quarter reached $131.00M , missing expectations by -6.77%.
Earnings released on 22 Feb 2023
EPS came in at -$0.37 surpassing the estimated -$1.06 by +65.09%, while revenue for the quarter reached $152.00M , missing expectations by -5.08%.
Earnings released on 9 Nov 2022
EPS came in at -$0.33 surpassing the estimated -$0.74 by +55.41%, while revenue for the quarter reached $159.77M , beating expectations by +10.99%.
Earnings released on 9 Aug 2022
EPS came in at -$0.74 falling short of the estimated -$0.61 by -21.31%, while revenue for the quarter reached $133.79M , missing expectations by -4.80%.
Earnings released on 4 May 2022
EPS came in at -$0.46 surpassing the estimated -$0.68 by +32.35%, while revenue for the quarter reached $141.92M , beating expectations by +15.89%.
Earnings released on 24 Feb 2022
EPS came in at $1.41 surpassing the estimated $0.28 by +403.57%, while revenue for the quarter reached $440.00M , beating expectations by +59.68%.
Earnings released on 3 Nov 2021
EPS came in at -$0.58 falling short of the estimated -$0.53 by -9.43%, while revenue for the quarter reached $133.09M , missing expectations by -18.68%.
Earnings released on 4 Aug 2021
EPS came in at -$0.57 falling short of the estimated -$0.56 by -1.79%, while revenue for the quarter reached $125.75M , missing expectations by -0.20%.
Earnings released on 5 May 2021
EPS came in at -$0.64 falling short of the estimated -$0.48 by -33.33%, while revenue for the quarter reached $111.61M , missing expectations by -19.42%.
Earnings released on 24 Feb 2021
EPS came in at -$2.44 falling short of the estimated $0.24 by -1.12K%, while revenue for the quarter reached $290.00M , beating expectations by +5.67%.
Earnings released on 4 Nov 2020
EPS came in at -$0.22 falling short of the estimated -$0.09 by -144.44%, while revenue for the quarter reached $160.08M , beating expectations by +144.44%.
IONS Stock Performance
Access detailed IONS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.